Francis Palisson

Francis Palisson

Auto-generated profile, based on publicly available information

Francis Palisson

Fundación DEBRA Chile Santiago Chile

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in International Wound Journal
Verified
Journal Article
Open access
IFIgnacia Fuentes
Ignacia Fuentes
MYMaría Joao Yubero
María Joao Yubero
PMPilar Morandé
Pilar Morandé
CVCarmen Varela Varela
Carmen Varela Varela
KOKaren Oróstica
Karen Oróstica
FPFrancis Palisson
Francis Palisson
Epidermolysis bullosa (EB) is an inherited disorder characterised by skin fragility and the appearance of blisters and wounds. Patient wounds are often colonised or infected with bacteria, leading to impaired healing, pain and high risk of death by sepsis. Little is known about the impact of bacterial composition and susceptibility in wound resolution, and there is a need for longitudinal studies to understand healing outcomes with different types of bacterial colonisation. A prospective longitudinal study of 70 wounds from 15 severe EB patients (Junctional and Recessive Dystrophic EB) from Chile. Wounds were selected independently of their infected status. Wound cultures, including bacterial species identification, composition and Staphylococcus aureus (SA) antibiotic susceptibility were registered. Wounds were separated into categories according to their healing capacity, recognising chronic, and healing wounds. Hundred‐one of the 102 wound cultures were positive for bacterial growth. From these, 100 were SA‐positive; 31 were resistant to Ciprofloxacin (31%) and only seven were methicillin‐resistant SA (7%). Ciprofloxacin‐resistant SA was found significantly predominant in chronic wounds (**P < .01). Interestingly, atoxigenic Corynebacterium diphtheriae (CD) was identified and found to be the second most abundant recovered bacteria (31/101), present almost always in combination with SA (30/31). CD was only found in Recessive Dystrophic EB patients and not related to wound chronicity. Other less frequent bacterial species found included Pseudomonas aeruginosa, Streptococus spp. and Proteus spp. Infection was negatively associated with the healing status of wounds.

2 August 2016 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
IFIgnacia Fuentes
Ignacia Fuentes
MJMário Campos Junior
Mário Campos Junior
GRGabriela M Repetto
Gabriela M Repetto
PMP. Morandé
P. Morandé
MYM.J. Yubero
M.J. Yubero
FPF. Palisson
F. Palisson

8 January 2025 in Oral Diseases
Verified
Journal Article
Open access
CBColomba Besa‐Witto
Colomba Besa‐Witto
AOAna Ortega-Pinto
Ana Ortega-Pinto
SVSebastián Véliz
Sebastián Véliz
MCMarco Cornejo-Ovalle
Marco Cornejo-Ovalle
IFIgnacia Fuentes
Ignacia Fuentes
SKSusanne Krämer
Susanne Krämer
Introduction: Junctional epidermolysis bullosa (JEB) is a rare genetic disease manifesting with skin and mucosal blistering. As part of the JEB, patients present with syndromic amelogenesis imperfecta (AI). Reports have described external crown resorption (ECR) in the teeth of patients with JEB, but its prevalence is unknown. Objective: To determine the prevalence of ECR in patients with JEB. Methods: A longitudinal retrospective cohort study was performed at the Special Care Dentistry Clinic, University of Chile. Clinical records of patients with JEB between 2005 and 2024 were analysed. Prevalence of ECR per patient, per type of tooth and per tooth was calculated. Results: Of the 20 patients examined, 90% presented ECR in at least one tooth, with an average of 4.8 primary and 6.8 permanent teeth affected. The most affected type of teeth were the incisors. 57.5% of primary incisors and 68% of permanent incisors had resorption. The most affected tooth was #82 in primary dentition (75%) and #32 in the permanent dentition (88.9%). Conclusions: The prevalence of ECR in patients with AI due to JEB caused by variants in LAMB3 was 90%. Establishing clinical and radiographic dental protocols for the early detection of ECR is essential to prevent extensive tooth destruction.

10 March 2024 in EMBO Molecular Medicine
Verified
Journal Article
Open access
GTGrace Tartaglia
Grace Tartaglia
IFIgnacia Fuentes
Ignacia Fuentes
NPNeil Patel
Neil Patel
AVAbigail Varughese
Abigail Varughese
LILauren Israel
Lauren Israel
ASAndrew P. South
Andrew P. South
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare inherited skin disease characterized by defects in type VII collagen leading to a range of fibrotic pathologies resulting from skin fragility, aberrant wound healing, and altered dermal fibroblast physiology. Using a novel in vitro model of fibrosis based on endogenously produced extracellular matrix, we screened an FDA-approved compound library and identified antivirals as a class of drug not previously associated with anti-fibrotic action. Preclinical validation of our lead hit, daclatasvir, in a mouse model of RDEB demonstrated significant improvement in fibrosis as well as overall quality of life with increased survival, weight gain and activity, and a decrease in pruritus-induced hair loss. Immunohistochemical assessment of daclatasvir-treated RDEB mouse skin showed a reduction in fibrotic markers, which was supported by in vitro data demonstrating TGFβ pathway targeting and a reduction of total collagen retained in the extracellular matrix. Our data support the clinical development of antivirals for the treatment of patients with RDEB and potentially other fibrotic diseases.